ACC 2019 External Validation Presentation for HART CAD
“Validation of Novel Biomarker-Clinical Score to Predict Presence of Obstructive Coronary Disease”
American College of Cardiology (ACC) Scientific Sessions, New Orleans, Louisiana
March 17, 2019
Undetected coronary artery disease (CAD) carries significant morbidity and mortality while remaining the leading cause of death.
A novel biomarker-based model to predict presence of CAD has potential to non-invasively diagnose CAD and has been shown to increase the accuracy of predicting clinically significant CAD in a prior exploratory study.
Study objective was to externally validate a recently developed proteomic assay’s ability to diagnose obstructive CAD (Prevencio HART CAD) in a prospective cohort of patients undergoing diagnostic catheterization.
Prospective patients referred to cardiac catheterization at single-center were enrolled and blood specimens were obtained pre-angiography. A total of 500 patients were enrolled over a 6-month period.
The score had a diagnostic odds ratio of 4.69 (p<0.001; 3.22, 6.84) and AUC 0.74 compared to original validation cohort (n=278) which had diagnostic odds ratio of 9.74 (p<0.001; 6.05, 16.1) and AUC 0.87.
Younger cohorts had AUC 0.81 and may demonstrate higher performance. Patients were referred for angiography for various acute and non-acute indications.
Scroll Down for ACC Presentation